Document is current
Any future updates will be listed below
-
Authors
Chesney, Jason
Lewis, Karl D
Kluger, Harriet
Hamid, Omid
Whitman, Eric https://orcid.org/0000-0001-7529-067X
Thomas, Sajeve
Wermke, Martin
Cusnir, Mike
Domingo-Musibay, Evidio https://orcid.org/0000-0002-2082-554X
Phan, Giao Q
Kirkwood, John M
Hassel, Jessica C https://orcid.org/0000-0001-7575-6230
Orloff, Marlana
Larkin, James
Weber, Jeffrey https://orcid.org/0000-0002-4962-2957
Furness, Andrew J S
Khushalani, Nikhil I https://orcid.org/0000-0002-3636-4143
Medina, Theresa
Egger, Michael E
Graf Finckenstein, Friedrich
Jagasia, Madan
Hari, Parameswaran
Sulur, Giri
Shi, Wen
Wu, Xiao
Sarnaik, Amod https://orcid.org/0000-0002-2337-5898
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02360579 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: <i>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</i>
https://doi.org/10.1136/jitc-2023-006947add1
789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)
https://doi.org/10.1136/jitc-2022-sitc2022.0789
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
https://doi.org/10.1136/jitc-2022-005755
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
https://doi.org/10.1200/jco.2024.42.16_suppl.9594
409 Multimodal single-cell sequencing analysis reveals putative tumor reactive population in lifileucel TIL products
https://doi.org/10.1136/jitc-2024-sitc2024.0409
371 Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL
https://doi.org/10.1136/jitc-2025-sitc2025.0371
776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study
https://doi.org/10.1136/jitc-2023-sitc2023.0776
P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
https://doi.org/10.1136/lba2019.18
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
-
Funding
Funding for this research was provided by:
Iovance Biotherapeutics (N/A)
- License Information
